Curis (NASDAQ:CRIS – Get Free Report) released its quarterly earnings results on Thursday. The biotechnology company reported ($2.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.91) by ($0.12), RTT News reports. Curis had a negative return on equity of 135.38% and a negative net margin of 460.45%. The company had […]
/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule.
/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today.
Curis, Inc. (NASDAQ:CRIS – Get Free Report)’s share price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $12.15 and traded as high as $12.16. Curis shares last traded at $11.87, with a volume of 42,605 shares. Analyst Ratings Changes A […]
Curis, Inc. (NASDAQ:CRIS – Get Free Report) saw a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 83,100 shares, a growth of 13.2% from the October 15th total of 73,400 shares. Based on an average daily trading volume, of 24,400 shares, the days-to-cover ratio […]